Contralateral weakness and fatigue after high-dose botulinum toxin injection for management of poststroke spasticity

American Journal of Physical Medicine and Rehabilitation

Volumn 88, Issue 6, 2009, Pages 495-499

  Varghese Kroll, Elizabeth ^a,b   Elovic, Elie P ^a,c,d  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b KESSLER INSTITUTE FOR REHABILITATION   (United States)

^c KESSLER FOUNDATION   (United States)

^d Foundation Research Center   (United States)

Author keywords

Adverse effects; Botulinum toxins; Muscle spasticity; Muscle weakness

Indexed keywords

BOTULINUM TOXIN A; ANTIPARKINSON AGENT; BOTULINUM TOXIN;

ADULT; ARTICLE; CASE REPORT; DRUG DOSE TITRATION; DRUG MEGADOSE; FATIGUE; FEMALE; HUMAN; OCCUPATIONAL THERAPY; PATIENT COMPLIANCE; PHYSICIAN; PHYSIOTHERAPY; RISK BENEFIT ANALYSIS; SPASTICITY; STROKE; TREATMENT DURATION; TREATMENT RESPONSE; WEAKNESS; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; MUSCLE WEAKNESS;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; FEMALE; HUMANS; MIDDLE AGED; MUSCLE SPASTICITY; MUSCLE WEAKNESS; STROKE;

EID: 66949179340     PISSN: 08949115     EISSN: None     Source Type: Journal    
DOI: 10.1097/PHM.0b013e3181a5b056     Document Type: Article

References (10)

1. Gordon MF, Brashear A, Elovic E, et al: Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 2004;63:1971-1973 (Pubitemid 39532408)
2. Turkel CC, Bowen B, Liu J, et al: Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch Phys Med Rehabil 2006;87:786-792 (Pubitemid 43767710)
3. Mancini F, Sandrini G, Moglia A, et al: A randomized, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci 2005;26:26-31 (Pubitemid 40723938)
4. Sheean G: Botulinum toxin treatment of adult spasticity: A benefit-risk assessment. Drug Saf 2006;29:31-48 (Pubitemid 43213894)
5. Goldstein EM: Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol 2006;21:189-192 (Pubitemid 43891142)
6. Naumann M, Albanese A, Heinen F, et al: Safety and efficacy of botulinum toxin type A following longterm use. Eur J Neurol 2006;13(suppl 4):35-40 (Pubitemid 44748282)
7. Gracies J-M, Elovic E, McGuire J, et al: Traditional pharmacologic treatments for spasticity. Part I. Local treatments, in Mayer NH, Simpson DM (eds): Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin. New York, NY: A WeMove Self-Study CME Activity, 2002, pp 44-64
8. Carruthers J, Carruthers A: Complications of botulinum toxin type A. Facial Plast Surg Clin North Am 2007;15:51-54
9. Batra RS, Dover JS, Arndt KA: Adverse event reporting for botulinum toxin type A. J Am Acad Dermatol 2005;53:1080-1082 (Pubitemid 41677338)
10. FDA Early Communication Notice. Early communication about an ongoing safety review Botox and Botox cosmetic (botulinum toxin type A) and Myobloc (botulinum toxin type B), February 8, 2008. Available at: http://www.fda.gov/ cder/drug/early-comm/botulinium-toxins.htm. Accessed October 5, 2008